Mobile

A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulat...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000965-21

A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulations of GlaxoSmithKline (GSK) Biologicals’ new generations meningococcal serogroups A, C, W-135, Y-tetanus toxoid conjugate (MenACWY-TT) vaccine versus one subcutaneous dose of MENCEVAX™ ACWY in healthy adolescents/young adults aged 15-19 years

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the immune response induced by four different formulations of GSK Biologicals’ new generations MenACWY-TT candidate conjugate vaccine versus MENCEVAX™ ACWY in healthy adolescents/young adults aged 15-19 years.

Critère d'inclusion

  • Primary immunization of healthy adolescents/young adults against meningococcal disease due to Neisseria meningitidis (N. meningitidis) of serogroups A, C, W-135 and Y

Liens